New oral drugs for erectile dysfunction

Drug and Therapeutics Bulletin

Volumn 42, Issue 7, 2004, Pages 49-52

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE GENITAL SYSTEM; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMYL NITRITE; ANTIHYPERTENSIVE AGENT; APOMORPHINE; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ERYTHROMYCIN; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; NITRIC ACID DERIVATIVE; NITRIC OXIDE DONOR; PAPAVERINE; PHENTOLAMINE; PHOSPHODIESTERASE V INHIBITOR; PROSTAGLANDIN E1; RITONAVIR; SAQUINAVIR; SILDENAFIL; TADALAFIL; VARDENAFIL;

ANAPHYLAXIS; ANGINA PECTORIS; BACKACHE; CLINICAL TRIAL; CONJUNCTIVITIS; COST OF ILLNESS; COUGHING; DIZZINESS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; EPISTAXIS; ERECTILE DYSFUNCTION; FACE EDEMA; FLUSHING; FOOD DRUG INTERACTION; GLAUCOMA; GRAPE JUICE; GRAPEFRUIT JUICE; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; INFECTION; LICENSING; MALE; MUSCLE HYPERTONIA; NAUSEA; NOSE CONGESTION; PAIN; PHARYNGITIS; PHOTOSENSITIVITY; PRIAPISM; PSYCHOGENIC IMPOTENCE; REVIEW; RHINITIS; SKIN MANIFESTATION; SLEEP DISORDER; SOMNOLENCE; SWEATING; SYNCOPE; TASTE DISORDER; UNITED KINGDOM; VASODILATATION; VISUAL DISORDER; YAWNING;

EID: 3543150187     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2004.42749     Document Type: Review

References (21)

1. Sildenafil for erectile dysfunction. DTB 1998; 36: 81-4.
2. The Process of Care Consensus Panel. The process of care model for evaluation and treatment of erectile dysfunction. Int J Impot Res 1999; 11: 59-70.
3. Prescription Pricing Authority. Drug Tariff June 2004. London: The Stationery Office, 2004; 567-8.
4. Uprima 2 & 3mg sublingual tablets. Summary of product characteristics, UK. Abbott Laboratories Ltd, March 2004.
5. Cialis. Summary of product characteristics, UK. Lilly ICOS Ltd, January 2004.
6. Levitra (vardenafil). Summary of product characteristics, UK. Bayer AG, March 2004.
7. von Keitz AT et al. A European multicentre study to evaluate the tolerability of apomorphine sublingual administered in a forced dose-escalation regimen in patients with erectile dysfunction. BJU Int 2002; 89: 409-15.
8. Dula E et al. Double-blind, crossover comparison of 3mg apomorphine SL with placebo and with 4mg apomorphine SL in male erectile dysfunction. Eur Urol 2001; 39: 558-64.
9. Perimenis P et al. A comparative, crossover study of the efficacy and safety of sildenafil and apomorphine in men with evidence of arteriogenic erectile dysfunction. Int J Impot Res 2004; 16: 2-7.
10. Buvat J, Montorsi F. Safety and tolerability of apomorphine SL in patients with erectile dysfunction. BJU Int 2001; 88 (suppl 3): 30-5.
11. Brock GB et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168: 1332-6.
12. Rosen RC et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-30.
13. Sáenz cle Tejada I et al. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002; 25: 2159-64.
14. Govier F et al. A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20mg or sildenafil citrate 50mg during initiation of treatment for erectile dysfunction. Clin Ther 2003; 25: 2709-23.
15. von Keitz A et al. A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. Eur Urol 2004; 45: 499-509.
16. Rajagopalan P et al. Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol 2003; 43: 260-7.
17. Hellstrom WJ et al. Vardenafil for treatmentof men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002; 23: 763-71.
18. Hellstrom WJ et al. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 2003; 61 (suppl 4A): 8-14.
19. Goldstein I et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes. A multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003; 26: 777-83.
20. Brock G et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol 2003; 170: 1278-83.
21. Porst H et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int. J Impot Res 2001; 13: 192-9.